Back to Search
Start Over
Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas.
- Source :
-
Leukemia & Lymphoma . Mar2016, Vol. 57 Issue 3, p635-643. 9p. - Publication Year :
- 2016
-
Abstract
- A phase 1 study with carfilzomib and vorinostat was conducted in 20 B-cell lymphoma patients. Vorinostat was given orally twice daily on days 1, 2, 3, 8, 9, 10, 15, 16, and 17 followed by carfilzomib (given as a 30-min infusion) on days 1, 2, 8, 9, 15, and 16. A treatment cycle was 28 days. Dose escalation initially followed a standard 3 + 3 design, but adapted a more conservative accrual rule following dose de-escalation. The maximum tolerated dose was 20 mg/m² carfilzomib and 100 mg vorinostat (twice daily). The dose-limiting toxicities were grade 3 pneumonitis, hyponatremia, and febrile neutropenia. One patient had a partial response and two patients had stable disease. Correlative studies showed a decrease in NF-κB activation and an increase in Bim levels in some patients, but these changes did not correlate with clinical response. [ABSTRACT FROM AUTHOR]
- Subjects :
- *CANCER relapse
*B cell lymphoma
*PNEUMONIA
*HYPONATREMIA
*FEBRILE neutropenia
Subjects
Details
- Language :
- English
- ISSN :
- 10428194
- Volume :
- 57
- Issue :
- 3
- Database :
- Academic Search Index
- Journal :
- Leukemia & Lymphoma
- Publication Type :
- Academic Journal
- Accession number :
- 113233125
- Full Text :
- https://doi.org/10.3109/10428194.2015.1075019